Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.47 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348836 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1HSD11B1CAMKK2 | |
| SCHEMBL3354642 | 1.00 | OPRL1 (0.52) | OPRL1OPRM1OPRK1HSD11B1CAMKK2 | |
| SCHEMBL16719380 | 0.86 | OPRL1 (0.64) | OPRL1OPRM1OPRK1HSD11B1CAMKK2 | |
| SCHEMBL3348838 | 0.82 | OPRL1 (0.57) | OPRL1OPRM1OPRK1HSD11B1JAK2 | |
| SCHEMBL12321753 | 0.82 | OPRL1 (0.57) | OPRL1OPRM1OPRK1HSD11B1JAK2 | |
| SCHEMBL3351315 | 0.82 | OPRL1 (0.57) | OPRL1OPRM1OPRK1HSD11B1JAK2 | |
| SCHEMBL3351276 | 0.82 | OPRL1 (0.57) | OPRL1OPRM1OPRK1HSD11B1JAK2 | |
| SCHEMBL4420976 | 0.79 | OPRL1 (0.71) | OPRL1OPRM1OPRK1HSD11B1CAMKK2 | |
| SCHEMBL6158491 | 0.78 | HSD11B1 (0.66) | OPRL1OPRM1OPRK1HSD11B1CCR2 | |
| SCHEMBL6633514 | 0.78 | OPRL1 (0.56) | OPRL1OPRM1OPRK1HSD11B1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | OPRL1 4619/4885OPRM1 4845/4885OPRK1 4194/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | OPRL1 4651/4885OPRM1 4853/4885OPRK1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.